Income Statement Interpace Biosciences, Inc.
Stocks
IDXG.D
US46062X4025
Healthcare Facilities & Services
|
Market Closed -
OTC Markets
15:53:58 2026-08-28 EDT
|
5-day change | 1st Jan Change | ||
| 7.618 USD | +5.08% |
|
+0.05% | +23.85% |
| Fiscal Period: December | 2016 (USD) | 2017 (USD) | 2018 (USD) | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 41.31M | 31.84M | 40.21M | 46.93M | 38.73M | |||||
Total Revenues | 41.31M | 31.84M | 40.21M | 46.93M | 38.73M | |||||
Cost of Goods Sold, Total | 23.37M | 13.61M | 16.31M | 17M | 14.6M | |||||
Gross Profit | 17.94M | 18.23M | 23.9M | 29.92M | 24.13M | |||||
Selling General & Admin Expenses, Total | 23.74M | 20.1M | 19.6M | 21.14M | 18.7M | |||||
R&D Expenses | 1.88M | 703K | 636K | 676K | 642K | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 4.06M | 1.27M | 861K | - | - | |||||
Other Operating Expenses, Total | 29.68M | 22.07M | 21.09M | 21.82M | 19.35M | |||||
Operating Income | -11.74M | -3.84M | 2.81M | 8.11M | 4.78M | |||||
Interest Expense, Total | -920K | -1.01M | -1.01M | -659K | -168K | |||||
Net Interest Expenses | -920K | -1.01M | -1.01M | -659K | -168K | |||||
Other Non Operating Income (Expenses) | -509K | -1.21M | -667K | -499K | -142K | |||||
EBT, Excl. Unusual Items | -13.17M | -6.06M | 1.14M | 6.95M | 4.47M | |||||
Restructuring Charges | - | - | - | - | -700K | |||||
Merger & Related Restructuring Charges | -2.58M | - | - | - | - | |||||
Asset Writedown | - | - | - | - | - | |||||
Other Unusual Items | 338K | 223K | -7K | - | - | |||||
EBT, Incl. Unusual Items | -15.41M | -5.84M | 1.13M | 6.95M | 3.77M | |||||
Income Tax Expense | -667K | 29K | 17K | 4K | -21.21M | |||||
Earnings From Continuing Operations | -14.75M | -5.86M | 1.11M | 6.95M | 24.98M | |||||
Earnings Of Discontinued Operations | -197K | -16.09M | -310K | -244K | -409K | |||||
Net Income to Company | -14.94M | -21.96M | 802K | 6.7M | 24.58M | |||||
Net Income - (IS) | -14.94M | -21.96M | 802K | 6.7M | 24.58M | |||||
Preferred Dividend and Other Adjustments | - | - | - | 464K | - | |||||
Net Income to Common Incl Extra Items | -14.94M | -21.96M | 802K | 6.24M | 24.58M | |||||
Net Income to Common Excl. Extra Items | -14.75M | -5.86M | 1.11M | 6.48M | 24.98M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -18.07 | -25.91 | 0.93 | 7.11 | 27.77 | |||||
Basic EPS - Continuing Operations | -17.83 | -6.92 | 1.29 | 7.39 | 28.24 | |||||
Basic Weighted Average Shares Outstanding | 827K | 848K | 863K | 877K | 885K | |||||
Net EPS - Diluted | -18.09 | -25.91 | 0.89 | 1.97 | 4.43 | |||||
Diluted EPS - Continuing Operations | -17.85 | -6.92 | 1.25 | 2.05 | 4.5 | |||||
Diluted Weighted Average Shares Outstanding | 827K | 848K | 873K | 3.15M | 5.54M | |||||
Normalized Basic EPS | -9.95 | -4.47 | 0.82 | 4.95 | 3.16 | |||||
Normalized Diluted EPS | -9.95 | -4.47 | 0.81 | 1.38 | 0.5 | |||||
Supplemental Items | ||||||||||
EBITDA | -6.66M | -1.28M | 3.84M | 8.41M | 5.21M | |||||
EBITA | -7.67M | -2.57M | 3.67M | 8.11M | 4.78M | |||||
EBIT | -11.74M | -3.84M | 2.81M | 8.11M | 4.78M | |||||
EBITDAR | -5.46M | -380K | 4.64M | 9.11M | 5.81M | |||||
Effective Tax Rate - (Ratio) | 4.33 | -0.5 | 1.51 | 0.06 | -562 | |||||
Current Domestic Taxes | -705K | 29K | 17K | 4K | 44K | |||||
Total Current Taxes | -705K | 29K | 17K | 4K | 44K | |||||
Deferred Domestic Taxes | 38K | - | - | - | -21.25M | |||||
Total Deferred Taxes | 38K | - | - | - | -21.25M | |||||
Normalized Net Income | -8.23M | -3.79M | 710K | 4.34M | 2.8M | |||||
Interest on Long-Term Debt | - | - | - | - | 168K | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 10.07M | 9.12M | 10.23M | 11.66M | 9.42M | |||||
General and Administrative Expenses | 13.67M | 10.97M | 9.36M | 9.49M | 9.28M | |||||
Research And Development Expense From Footnotes | 1.88M | 703K | 636K | 676K | 642K | |||||
Net Rental Expense, Total | 1.2M | 900K | 800K | 700K | 600K | |||||
Imputed Operating Lease Interest Expense | 957K | 541K | 473K | 433K | 229K | |||||
Imputed Operating Lease Depreciation | 243K | 359K | 327K | 267K | 371K | |||||
Stock-Based Comp., Other (Total) | 1.37M | 1.24M | 630K | 291K | 35K | |||||
Total Stock-Based Compensation | 1.37M | 1.24M | 630K | 291K | 35K |
- Stock Market
- Stocks
- IDXG.D Stock
- Financials Interpace Biosciences, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















